The paper evaluates the results of therapy in patients with glottic larynx cancer in the stage T1 and T2. The cohort of 166 patients has been treated at our clinic in the years 1980 to 2000. The period of observation since operation was 3 to 23 years. The age of the patients was in the range of 35 and 91 years, the ratio of men and women was 12:1. The relapse or persistence of larynx cancer after therapy was diagnosed in 41 patients, representing 25% of the cohort. Three years after the therapy 141 patients survived (85%) and 133 patients (80%) survived for the period of five years. Fourteen patients died in connection with larynx cancer, representing 8% of the cohort. Specific five-year survival in the whole cohort is therefore 92%. Among 41 patients treated for the relapse or persistence of the tumour, 27 proved to survive without sign of the tumour, representing 66% of this subgroup. The relapse of larynx cancer occurred most often in tumours of the T2 stage, most rarely in T1a tumours, where the percentage of relapses proved to be 15%. The relapses occurred more frequently after actinotherapy than after surgery or after a combined therapy. In evaluating individual kinds of surgical treatment, relapse or persistence of tumour occurred more often after endolaryngeal treatment than after surgery from external approach. Frequent relapses of the primary focus developed in cases, where a positive margin was proved by histology, in cases of low differentiation of the tumour and in patients with metastatic affection of lymphatic nodes.

        Key words: glottic larynx cancer.